Breaking News, Collaborations & Alliances

Harbour BioMed, Kelun-Biotech Enter Agreement

To develop & commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of Greater China

Harbour BioMed has entered into an exclusive strategic partnership with Kelun-Biotech to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region. The companies will also collaborate in developing combination therapies of A167 with other agents for commercialization in their respective territories. The potential value of the partnership exceeds $350 million in addition to royalties. “Anti-PD-L1 therapy has been valid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters